Is the "3+3" dose-escalation Phase i Clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design

Osama E. Rahma, Emily Gammoh, Richard M. Simon, Samir N. Khleif

Research output: Contribution to journal › Article › peer-review

41 Scopus citations

Fingerprint

Dive into the research topics of 'Is the "3+3" dose-escalation Phase i Clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design'. Together they form a unique fingerprint.

Medicine & Life Sciences